AEON Biopharma, Inc. has announced its financial results for the first quarter ended March 31, 2025. The company, focused on developing a botulinum toxin complex for therapeutic treatments, is actively advancing the biosimilar development program for ABP-450 using BOTOX as a reference product. AEON is pursuing the 351(k) regulatory pathway to potentially access the U.S. market with a single FDA approval covering all current and future therapeutic indications of BOTOX. The company recently appointed Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft, who brings over 25 years of leadership experience in the life sciences industry, was also appointed to AEON's Board of Directors. Prior to AEON, he successfully led the launch of Daxxify® for Revance Therapeutics. Additionally, the NYSE American LLC has accepted AEON's plan to regain compliance with continued listing standards related to minimum market capitalization and stockholders' equity, granting the company until August 3, 2026, to meet these standards. This development is subject to ongoing monitoring.